CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme

被引:78
作者
Martinez, Ramon
Setien, Fernando
Voelter, Christiane
Casado, Sara
Quesada, Maria P.
Schackert, Gabriele
Esteller, Manel
机构
[1] Univ Dresden, Dept Neurosurg, D-01307 Dresden, Germany
[2] Spanish Natl Canc Ctr, CNIO, Epigenet Lab, E-28029 Madrid, Spain
[3] Univ Wurzburg, ENT Dept, D-97080 Wurzburg, Germany
关键词
D O I
10.1093/carcin/bgm014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme (GBM) is an incurable malignancy with inherent tendency to recur. In this study, we have comparatively analyzed the epigenetic profile of 32 paired tumor samples of relapsed GBM and their corresponding primary neoplasms with special attention to genes involved in the mitochondria-independent apoptotic pathway. The CpG island promoter hypermethylation status was assessed by methylation-specific polymerase chain reaction and selected samples were double checked by bisulfite genomic sequencing. Thirteen genes were analyzed for DNA methylation: the pro-apoptotic CASP8, CASP3, CASP9, DcR1, DR4, DR5 and TMS1; the cell adherence CDH1 and CDH13; the candidate tumor suppressor RASSF1A and BLU; the cell cycle regulator CHFR and the DNA repair MGMT. The CpG island promoter hypermethylation profile of relapsed GBM in comparison with their corresponding primary tumors was identical in 37.5% of the cases, whereas in 62.5% of patients, differences in the DNA methylation patterns of the 13 genes were observed. The most prominent distinction was the presence of previously undetected CASP8 hypermethylation in the GBM relapses (P = 0.031). This finding was also linked to the observation that an unmethylated CASP8 CpG island together with methylated BLU promoter in the primary GBM was associated with prolonged time to tumor progression (P = 0.0035). Our data strongly suggest that hypermethylation of the pro-apoptotic CASP8 is a differential feature of GBM relapses. These remarkable findings may foster the development of therapeutic approaches using DNA demethylating drugs and activators of the extrinsic apoptotic pathway to improve the dismal prognosis of GBM.
引用
收藏
页码:1264 / 1268
页数:5
相关论文
共 42 条
[21]   CLONAL ANALYSIS OF HUMAN ASTROCYTOMAS [J].
MORSE, RP ;
DARRAS, BT ;
YE, Z ;
WU, JK .
JOURNAL OF NEURO-ONCOLOGY, 1994, 21 (02) :151-157
[22]   Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene [J].
Nakamura, M ;
Watanabe, T ;
Yonekawa, Y ;
Kleihues, P ;
Ohgaki, H .
CARCINOGENESIS, 2001, 22 (10) :1715-1719
[23]   DNA damage-induced apoptosis [J].
Norbury, CJ ;
Zhivotovsky, B .
ONCOGENE, 2004, 23 (16) :2797-2808
[24]   An antagonist decoy receptor and a death domain-containing receptor for TRAIL [J].
Pan, GH ;
Ni, J ;
Wei, YF ;
Yu, GL ;
Gentz, R ;
Dixit, VM .
SCIENCE, 1997, 277 (5327) :815-818
[25]   CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas [J].
Paz, MF ;
Yaya-Tur, R ;
Rojas-Marcos, I ;
Reynes, G ;
Pollan, M ;
Aguirre-Cruz, L ;
García-Lopez, JL ;
Piquer, J ;
Safont, MJ ;
Balaña, C ;
Sanchez-Cespedes, M ;
García-Villanueva, M ;
Arribas, L ;
Esteller, M .
CLINICAL CANCER RESEARCH, 2004, 10 (15) :4933-4938
[26]   Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family [J].
Pitt, RM ;
Marsters, SA ;
Ruppert, S ;
Donahue, CJ ;
Moore, A ;
Ashkenazi, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :12687-12690
[27]  
Ralte Angela Mercy, 2001, Pathology and Oncology Research, V7, P267
[28]   Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1) [J].
Rehemtulla, A ;
Hamilton, CA ;
Chinnaiyan, AM ;
Dixit, VM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (41) :25783-25786
[29]  
Salcman M, 1991, NEUROLOGY BRAIN TUMO, P1339
[30]   Comparative molecular genetic profiles of anaplastic astrocytomas glioblastomas multiforme and their subsequent recurrences [J].
Saxena, A ;
Shriml, LM ;
Dean, M ;
Ali, IU .
ONCOGENE, 1999, 18 (06) :1385-1390